Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: GlobeNewswire
Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program designed to develop and progress innovative oncology projects LA JOLLA, Calif., March 19, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced that it has been accepted into the first round of the Alderley Park Oncology Development Program, a UK national program designed to offer advice, guidance, and financial support to develop and progress innovative oncology projects. The Alderley Park Oncology Development Program is funded by Innovate UK and Cancer Research UK and supported by major oncology-focused pharmaceutical companies including, AstraZeneca, J&J, GSK and Roche. Artelo’s app
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateGlobeNewswire
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeGlobeNewswire
- Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th [Yahoo! Finance]Yahoo! Finance
ARTL
Analyst Actions
- 4/2/24 - HC Wainwright
ARTL
Sec Filings
- 3/29/24 - Form S-8
- 3/25/24 - Form 10-K
- 3/4/24 - Form 8-K
- ARTL's page on the SEC website